ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1338

Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis

Sagarika Dey1, Gloria Spratt2, Muguet Koobasi3, Carol Vleeskens4, Carlos El-Haddad5 and Ayano Kelly6, 1School of Clinical Medicine, South Western Sydney Campus, University of New South Wales, Parramatta, New South Wales, Australia, 2Physiotherapy Department and Rheumatology Department, Liverpool Hospital; Zone34 Sports Physiotherapy, Liverpool, Australia, 3Knowledge Centre for Health Ghent, Ghent University, Ghent, Belgium, 4Sydney Partnership for Health Medical Research and Enterprise Consumer Community Council, Liverpool, Australia, 5Rheumatology Department, Liverpool Hospital, Liverpool, Australia, 6South Western Sydney Campus, UNSW Medicine & Health, Braddon, Australia

Meeting: ACR Convergence 2022

Keywords: osteopenia, osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Suboptimal adherence to anti-osteoporotic medications presents a growing social and economic concern. Yet, it is unclear what patients’ perspectives and experiences are regarding medication use, and how these vary across phases of adherence, patients’ identities and various anti-osteoporotic medications. We aimed to describe patients’ perspectives and experiences of medication use in osteoporosis, to inform person-centred interventions that improve adherence and patient outcomes.

Methods: Databases (MEDLINE, Embase, PsycINFO and CINAHL) were searched for qualitative studies reporting on the perspectives and experiences of adults (≥18 years) with osteoporosis and/or osteopenia, and regarding anti-osteoporotic medications, in any language until February, 2022. Inductive thematic analysis was performed. Multiple investigators, including a consumer with lived experience of osteoporosis, have been integral to data analysis.

Results: From 35 articles with 853 adults with osteoporosis or osteopenia, four themes (with sub-themes) were identified:

  • denial of susceptibility (an invisible disease, unfitting the stereotype, zero tolerance for risks);
  • disempowered in healthcare relationships (disconnected care, confusion from conflicting advice, resigned to strained communication);
  • fear of jeopardising normalcy (confronting deterioration and dependency, unnatural and unpredictably toxic, overwhelmed by commitment, deterred by negative experiences);
  • desiring affirmative support (confidence in empathy, mirroring doctors’ persistence, bonding through shared experiences, security in evidence, seeking knowledge and guidance to regain control)
  • Conclusion: Patients’ perceptions of vulnerability, confidence in healthcare relationships, attitudes towards change and accessible support systems can influence their commitment to medication-taking. Offering tailored education may empower patients to make informed decisions regarding treatment risks and benefits, and participate confidently in shared-decision making. Greater time and consistent communication devoted to patients’ concerns and expectations can foster a supportive environment that may alleviate the fear and uncertainty associated with adjusting to medications. Continued emphasis on treatment benefits and avenues to voice emerging concerns may promote long-term adherence and health outcomes. Further studies evaluating adherence-improving strategies through the consumers’ lens are vital to drive the development of more informed, person-centred interventions and optimise physical, psychosocial and functional outcomes.


    Disclosures: S. Dey, None; G. Spratt, None; M. Koobasi, None; C. Vleeskens, None; C. El-Haddad, None; A. Kelly, None.

    To cite this abstract in AMA style:

    Dey S, Spratt G, Koobasi M, Vleeskens C, El-Haddad C, Kelly A. Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/patients-perspectives-and-experiences-of-medication-use-in-osteoporosis-a-qualitative-systematic-review-and-thematic-synthesis/. Accessed .
    • Tweet
    • Email
    • Print

    « Back to ACR Convergence 2022

    ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-perspectives-and-experiences-of-medication-use-in-osteoporosis-a-qualitative-systematic-review-and-thematic-synthesis/

    Advanced Search

    Your Favorites

    You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

    All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

    Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

    Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

    Wiley

    • Online Journal
    • Privacy Policy
    • Permissions Policies
    • Cookie Preferences

    © Copyright 2025 American College of Rheumatology